Optimizing Mitral Valve Replacement Outcomes: The Role of Goal-Directed Hemodynamic and Fluid Therapy in the Perioperative Period

Background: There is no doubt that hemodynamic monitoring plays a crucial role in cardiac surgery. Research is generally aimed to identify optimal strategies for maintaining hemodynamic stability, reducing complications, and minimizing recovery time after surgery.

Objective: To study the effect of echocardiography-guided goal-directed hemodynamic and fluid therapy on perioperative outcomes of mitral valve replacement (MVR).

Material and methods: We analyzed data from 146 patients with mitral regurgitation who underwent MVR. The patients were grouped by standard hemodynamic therapy (comparison group, n=74) and goal-directed therapy (main group, n=72). The study groups were representative, and preoperative clinical, laboratory, and imaging data did not differ significantly between the groups. The study period began with the induction of general anesthesia and ended with hemodynamic stabilization achieved. This point of clinical recovery was defined as the successful extubation and absence of vasoactive support; the dose of inotropes and/or vasopressors was either completely weaned off or remained unchanged for >8 hours.

Results: The study groups differed in several key parameters. The anesthesia time decreased from 255 to 223 minutes (P=.02), and the cardiopulmonary bypass time from 94 to 82 minutes (P<.001). The volume of fluids until hemodynamic stabilization was achieved was higher in the comparison group (P=.002). Inotropes were used more often in the comparison group (P><.05). The mechanical ventilation time in the main group and the comparison group was 7.33 and 13 hours, respectively (P><.001); the intensive care unit length of stay was 1.1 and 1.8 hours (P=.014), respectively. The incidence of acute myocardial ischemia was lower in the main group (2.8% vs 12.2%, P=.026). Conclusions: Goal-directed hemodynamic and fluid therapy significantly improves MVR outcomes and reduces the risk of postoperative complications and long-term use of cardiovascular drugs.> <.001) . The volume of fluids until hemodynamic stabilization was achieved was higher in the comparison group (P=.002). Inotropes were used more often in the comparison group (P <.05) ). The mechanical ventilation time in the main group and the comparison group was 7.33 and 13 hours, respectively (P <.001) ; the intensive care unit length of stay was 1.1 and 1.8 hours (P=.014), respectively. The incidence of acute myocardial ischemia was lower in the main group (2.8% vs 12.2%, P=.026).

Conclusions: Goal-directed hemodynamic and fluid therapy significantly improves MVR outcomes and reduces the risk of postoperative complications and long-term use of cardiovascular drugs.

1. VahanianA, Beyersdorf F, Praz F, et al; ESC/EACTS Scientific Document Group. 2021 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J. 2022;43(7):561–632. Published correction appears in Eur Heart J. 2022;43(21):2022. PMID: 34453165. https://doi.org/10.1093/eurheartj/ehab395

2. Maganti K, Rigolin VH, Sarano ME, Bonow RO. Valvular heart disease: diagnosis and management. Mayo Clin Proc. 2010;85(5):483–500. PMID: 20435842. PMCID: PMC2861980. https://doi.org/10.4065/mcp.2009.0706

3. Kaneko T, Cohn LH. Mitral valve repair. Circ J. 2014;78(3):560– 566. PMID: 24492161. https://doi.org/10.1253/circj.cj-14-0069

4. Grant MC, Salenger R, Lobdell KW. Perioperative hemodynamic monitoring in cardiac surgery. Curr Opin Anaesthesiol. 2024;37(1):1–9. PMID: 38085877. https://doi.org/10.1097/ACO.0000000000001327

5. Sidebotham DA, Allen SJ, Gerber IL, Fayers T. Intraoperative transesophageal echocardiography for surgical repair of mitral regurgitation. J Am Soc Echocardiogr. 2014;27(4):345–366. PMID: 24534653. https://doi.org/10.1016/j.echo.2014.01.005

6. Zoghbi WA, Adams D, Bonow RO, et al. Recommendations for noninvasive evaluation of native valvular regurgitation: a report from the American Society of Echocardiography developed in collaboration with the Society for Cardiovascular Magnetic Resonance. J Am Soc Echocardiogr. 2017;30(4):303–371. PMID: 28314623. https://doi.org/10.1016/j.echo.2017.01.007

7. Kontar L, Beaubien-Souligny W, Couture EJ, et al. Prolonged cardiovascular pharmacological support and fluid management after cardiac surgery. PLoS One. 2023;18(5):e0285526. PMID: 37167244. PMCID: PMC10174538. https://doi.org/10.1371/journal.pone.0285526

8. Williams JB, Hernandez AF, Li S, et al. Postoperative inotrope and vasopressor use following CABG: outcome data from the CAPS-care study. J Card Surg. 2011;26(6):572–578. PMID: 21951076. PMCID: PMC3677728. https://doi.org/10.1111/j.1540-8191.2011.01301.x

9. Khwaja A. KDIGO clinical practice guidelines for acute kidney injury. Nephron Clin Pract. 2012;120(4):c179–c184. PMID: 22890468. https://doi.org/10.1159/000339789

10. Dolgin M. Nomenclature and Criteria for Diagnosis of Diseases of the Heart and Great Vessels. 9th ed. Little, Brown & Co; 1994:253–256.

11. Nashef SA, Roques F, Michel P, Gauducheau E, Lemeshow S, Salamon R. European system for cardiac operative risk evaluation (EuroSCORE). Eur J Cardiothorac Surg. 1999;16(1):9–13. PMID: 10456395. https://doi.org/10.1016/s1010-7940(99)00134-7

12. Aya HD, Cecconi M, Hamilton M, Rhodes A. Goal-directed therapy in cardiac surgery: a systematic review and meta-analysis. Br J Anaesth. 2013;110(4):510–517. PMID: 23447502. https://doi.org/10.1093/bja/aet020

13. Giglio M, Dalfino L, Puntillo F, Rubino G, Marucci M, Brienza N. Haemodynamic goal-directed therapy in cardiac and vascular surgery. A systematic review and meta-analysis. Interact Cardiovasc Thorac Surg. 2012;15(5):878–887. PMID: 22833509. PMCID: PMC3480598. https://doi.org/10.1093/icvts/ivs323

14. Doherty M, Buggy DJ. Intraoperative fluids: how much is too much?. Br J Anaesth. 2012;109(1):69–79. PMID: 22661747. https://doi.org/10.1093/bja/aes171

15. McGee WT, Raghunathan K. Physiologic goal-directed therapy in the perioperative period: the volume prescription for high-risk patients. J Cardiothorac Vasc Anesth. 2013;27(6):1079– 1086. PMID: 24075639. https://doi.org/10.1053/j.jvca.2013.04.019

16. Fergerson BD, Manecke GR Jr. Goal-directed therapy in cardiac surgery: are we there yet?. J Cardiothorac Vasc Anesth. 2013;27(6):1075–1078. PMID: 24267575. https://doi.org/10.1053/j.jvca.2013.08.004

17. Arulkumaran N, Corredor C, Hamilton MA, et al. Cardiac complications associated with goal-directed therapy in high-risk surgical patients: a meta-analysis. Br J Anaesth. 2014;112(4):648– 659. PMID: 24413429. https://doi.org/10.1093/bja/aet466

18. Osawa EA, Rhodes A, Landoni G, et al. Effect of perioperative goal-directed hemodynamic resuscitation therapy on outcomes following cardiac surgery: a randomized clinical trial and systematic review. Crit Care Med. 2016;44(4):724–433. PMID: 26646462. https://doi.org/10.1097/CCM.0000000000001479

19. Saraf S, Karnad DR. Goal-directed therapy: does it work in postcardiac surgery patients, unlike in sepsis?. Indian J Crit Care Med. 2020;24(5):287–288. PMID: 32728314. PMCID: PMC7358854. https://doi.org/10.5005/jp-journals-10071-23452

20. Engelman DT, Ben Ali W, Williams JB, et al. Guidelines for perioperative care in cardiac surgery: Enhanced Recovery After Surgery Society recommendations. JAMA Surg. 2019;154(8):755–766. PMID: 31054241. https://doi.org/10.1001/jamasurg.2019.1153

21. Patel H, Parikh N, Shah R, et al. Effect of goal-directed hemodynamic therapy in postcardiac surgery patients. Indian J Crit Care Med. 2020;24(5):321–326. PMID: 32728322. PMCID: PMC7358857. https://doi.org/10.5005/jp-journals-10071-23427

22. January CT, Wann LS, Alpert JS, et al; ACC/AHA Task Force Members. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation. 2014;130(23):2071–2104. Published correction appears in Circulation. 2014;130(23):e270-1. PMID: 24682348. https://doi.org/10.1161/CIR.0000000000000040

23. Baumgartner H, Falk V, Bax JJ, et al; ESC Scientific Document Group. 2017 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J. 2017;38(36):2739–2791. PMID: 28886619. https://doi.org/10.1093/eurheartj/ehx391.